Drug Trial Radar · NCT07553442
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
93
Planned (sponsor's estimate)
Start
Apr 27, 2026
Primary completion
Apr 1, 2028
Study completion Oct 1, 2028
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- Collaborators
- Hoffmann-La Roche
- First posted
- Apr 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Conditions
- Hypertension
Interventions
ALN-AGT01 RVRDrug
ALN-AGT01 RVR will be administered subcutaneously (SC)
PlaceboDrug
Placebo will be administered SC
ZilebesiranDrug
Zilebesiran will be administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage recovery from baseline in serum AGTTime frame: Up to Day 4
- Part B: Percentage recovery from baseline in mean seated office SBPTime frame: At Day 4 and Day 7
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Lake Forest, California · Recruiting
Clinical Trial Site
Tampa, Florida · Active not recruiting
Clinical Trial Site
Savannah, Georgia · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.